<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703364</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_CLL-9</org_study_id>
    <secondary_id>2011-004912-43</secondary_id>
    <nct_id>NCT01703364</nct_id>
  </id_info>
  <brief_title>Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL</brief_title>
  <official_title>Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Escalating Starting Dose of Lenalidomide and Concomitant Evaluation of Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial in patients with previously untreated CLL. Eligible patients will receive&#xD;
      Lenalidomide with a backbone of Fludarabine and Rituximab for 6 therapy cycles. Lenalidomide&#xD;
      will be increased by dose steps of 5 mg every cycle in the absence of limiting toxicity. If&#xD;
      limiting toxicity ensues the patients will be treated with last tolerable dose for the&#xD;
      remainder of the 6 treatment cycles.&#xD;
&#xD;
      The first 5 patients will start with dose level 5 mg Lenalidomide and further escalating&#xD;
      dose. After the fifth patient is included in the study, enrolment will be interrupted until&#xD;
      this patient has finished his first treatment cycle. A safety board will evaluate the&#xD;
      toxicities of the first 5 patients. If there are more than 2 patients experiencing a dose&#xD;
      limiting toxicity (DLT) in the first treatment cycle, the starting dose will not be escalated&#xD;
      and further 5 patients will be enrolled with a starting dose of 5 mg Lenalidomide. If only 2&#xD;
      or less patients experience a DLT in the first treatment cycle, the next 5 patients will&#xD;
      start the treatment with 10 mg Lenalidomide.&#xD;
&#xD;
      The rational for the higher starting doses stems from the lack of tumor lysis or tumor flare&#xD;
      toxicity in this combination on the one hand and from the observation that the very slow&#xD;
      escalation from 2,5 mg on led to a lack of efficacy in monotherapy trials due to early&#xD;
      progression in a relevant number of cases. The increase of the Lenalidomide dosage should&#xD;
      result in an increased efficacy especially at the beginning and a higher cumulative dose of&#xD;
      Lenalidomide.&#xD;
&#xD;
      The identification of patients intolerant to Lenalidomide by immunophenotyping of the T cells&#xD;
      for validation is also part of this trial, because intolerance seems to be not dose dependent&#xD;
      but may be caused by T cell activation. Therefore, early identification of patients&#xD;
      intolerant to this form of modern immunochemotherapy and establishing efficient Lenalidomide&#xD;
      based combination therapy is an important part of improvement of current CLL treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of escalated starting dose</measure>
    <time_frame>12 month, 20 month</time_frame>
    <description>Interim analysis after completion of cylce 1 of the first 5 patients, final analysis after last pastient last visit Metrics: Number of patients experiencing defined dose limiting toxicities during cycle 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishment of maximal tolerated dose (MTD) of Lenalidomide in combination with FR</measure>
    <time_frame>20 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to MTD</measure>
    <time_frame>20 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of the FRL combination</measure>
    <time_frame>20 month</time_frame>
    <description>Analysis of occuring adverse events during the study treatment according to Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in all phases by 4-colour flow cytometric and ASO-PCR MRD analysis</measure>
    <time_frame>20 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factor analysis (FISH cytogenetics, CD38/ZAP-70 expression, mutation status)</measure>
    <time_frame>20 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal definition of T cell subsets (including prognostic EM T cells and Treg cells)+/- PD1</measure>
    <time_frame>20 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>CLL</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Lenalidomide/Fludarabine/Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs&#xD;
Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days&#xD;
Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs&#xD;
Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days&#xD;
Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days</description>
    <arm_group_label>Lenalidomide/Fludarabine/Rituximab</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Male or female ≥ 18 years of age&#xD;
&#xD;
          -  CLL (as determined by CD23+, CD5+, CD19+)&#xD;
&#xD;
          -  Treatment indication as defined by the NCI Workshop criteria (see appendix 6 and&#xD;
             reference 10)&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  No previous treatment of the CLL by chemotherapy, radiotherapy (except localized&#xD;
             radiotherapy of 1 lymphatic area) or immunotherapy&#xD;
&#xD;
          -  Life expectancy &gt; 6 months (except prognosis due to high risk CLL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active bacterial, viral or fungal infection&#xD;
&#xD;
          -  Positivity for HIV, Hepatitis B or C&#xD;
&#xD;
          -  Patients with known history of thromboembolic events&#xD;
&#xD;
          -  Reduced organ functions and bone marrow dysfunction not due to CLL&#xD;
&#xD;
          -  Creatinine clearance of below 30 ml/min&#xD;
&#xD;
          -  Patients with known history of thromboembolic events&#xD;
&#xD;
          -  Patients with a history of other malignancies within 2 years prior to study entry&#xD;
             (except for adequately treated carcinoma in situ of the cervix; basal or squamous cell&#xD;
             skin cancer; low grade, early stage localized prostate cancer treated surgically with&#xD;
             curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with&#xD;
             curative intent)&#xD;
&#xD;
          -  Patients with medical co-morbid conditions that would require long term use (&gt; 1&#xD;
             month) of systemic corticosteroids during study treatment&#xD;
&#xD;
          -  Patients with a history of severe cardiac disease; e.g. NYHA Functional Class III or&#xD;
             IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias&#xD;
             requiring ongoing treatment, or unstable angina&#xD;
&#xD;
          -  Other known co-morbidity with the potential to dominate survival&#xD;
&#xD;
          -  Transformation to aggressive B-cell malignancy (e.g., large B-cell lymphoma, Richter's&#xD;
             syndrome, or prolymphocytic leukemia (PLL))&#xD;
&#xD;
          -  Hypersensitivity with anaphylactic reaction to humanised monoclonal antibodies or any&#xD;
             of the applied drugs&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
             indicated in the study protocol&#xD;
&#xD;
          -  Administration of any investigational agent(s) within 4 weeks prior to entry&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Medical or psychological condition which in the opinion of the Investigator would not&#xD;
             permit the patient to complete the study or sign meaningful informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.agmt.at</url>
    <description>AGMT</description>
  </link>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>AGMT</keyword>
  <keyword>T cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

